Market Trends of Netherlands In-Vitro Diagnostics Industry
This section covers the major market trends shaping the Netherlands In Vitro Diagnostics Market according to our research experts:
The Molecular Diagnostics Segment is Expected to Register Significant Growth in the Netherlands In Vitro Diagnostics Market Over the Forecast Period
The molecular diagnostic segment is anticipated to witness growth in the market owing to the factors such as a rise in chronic diseases that require early diagnosis and the increasing demand for point-of-care testing and personalized medicine. Molecular diagnostic devices are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. Additionally, the incidence of cancer in the Netherlands is also expected to drive the growth of molecular diagnostics owing to the growing demand for effective diagnostics. For instance, as per the Netherlands Comprehensive Cancer Organisation (IKNL), in 2032, there are likely to be about 156,000 new diagnoses of cancer. This means that in less than ten years, an average of 18 people per hour will be diagnosed with cancer.
Furthermore, according to VZinfo, in 2021, an estimated 1,156,900 people with diabetes were living in the Netherlands (The number of people who have had a particular disease during a given year). These were 618,300 men and 538,500 women (70.9 per 1,000 men and 61.1 per 1,000 women). Diabetes is more common in men than women in almost all age groups in the Netherlands. Thus, in some cases due to the genetic etiology of monogenic diabetes, molecular diagnostics can be used for diagnosis and classification.
New product launches in the Netherlands are also expected to drive the growth of the studied segment during the forecast period. For instance, in August 2022 IncellDx received the CE marking for a long-COVID blood test that will be launched in the European markets. Similarly, in December 2021 PathoFinderand EWC Diagnostics partnered to rapidly advance the expansion of COVID-19 testing capacity in the Netherlands by providing the Dutch government with complete sets of sampling materials and SARS-CoV-2 PCR kits.
The Infectious Disease Segment is Expected to Register the Fastest Growth in the Netherlands IVD Market Over the Forecast Period
The infectious disease segment is anticipated to witness the fastest growth in the market owing to the factors such as a rise in infectious diseases across the country. For instance, per a Communicable Disease Threats Report in November 2022, the number of monkeypox cases reported in the Netherlands was 1,248 in November 2022, whereas the count was 1,221 in September 2022. As per the same source, 4 cases of diphtheria were reported in 2022. Furthermore, per a 2022 update from VZinfo.nl, the incidence of influenza cases in the Netherlands in 2021 was 341 for the age group 0 to 4 years.
Furthermore, laboratory services launches and government initiatives to eradicate infectious diseases are likely to boost the market growth. For instance, in May 2022, Eurofins Scientific, a company focused on bioanalytical testing, signed an agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie, a medical microbiology and pathology laboratory diagnostics company in the Netherlands. PAMM serves six hospitals in the Netherlands, including two top-rated clinical oncology centers, general practitioners, and independent treatment centers. The lab specializes in medical microbiology and pathology and was the first in the Netherlands to have implemented full digital pathology.
